THE EUROPEAN LEAD FACTORY:
LEADING THE WAY
to the discovery of new medicines

In collaboration with charities and foundations
The European Lead Factory (ELF) is a collaborative public-private partnership that exists to boost drug discovery in all disease areas. It combines the innovation of academia, the agility of SMEs and the experience of large pharmaceuticals.

Previously only open to European researchers eligible for IMI funding, the ELF is now offering its services to charities, foundations, and other not-for-profits around the world.

THE EUROPEAN LEAD FACTORY: WORKING WITH YOU to give your drug discovery programme a major boost
An experienced initiative, the ELF has been running since 2013. Different partners contribute with different expertise and assets, and together we operate a not-for-profit drug discovery platform that includes assay development, high throughput and high content screening, as well as hit selection and hit resynthesis.

Screening takes place on sub-set of ELF Compound Library, a high-quality collection of compounds that is only accessible via the ELF. Over the years, the ELF has delivered on many screening programmes and contributed to various accomplishments.

YOUR AMBITIONS
Are you working on a particular target, phenotype, or in a certain disease area, and would like to find compounds that can lead to novel drug starting points? Please contact us so that we can discuss what we can do for you.

COLLECTIVE INTELLIGENCE
for creating new medicines
BY PARTNERING WITH US, you will:

• Gain access to the ELF assets and infrastructure (high-quality compound library and state-of-the-art screening facilities)

• Contribute to global health and well-being by leveraging business opportunities in Europe and beyond

• Explore uncharted biological territory through the sourcing of new targets, pathways, and phenotypes to address unmet medical needs

WORK WITH US and…

• Give your drug discovery programme a major boost

• Play a role in creating a more competitive drug discovery landscape that will have a greater impact on society

• Help expand the thriving life sciences and health sector

• Contribute to new scientific breakthroughs

The ELF is well-positioned to be the partner of choice to move your science forward towards new therapies.
MMV is a not-for-profit product development partnership (PDP) working to reduce the burden of malaria by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV has been partnering with the European Lead Factory (ELF) since 2018 to run high-throughput screens for novel antimalarials.

The ELF is a hub for making drug discovery happen. It brings together international leaders and provides a safe space for the exchange of knowledge and data. It connects experts with different skill sets, helping to establish a robust research network of public and private partners focused on drug development.
KEY HIGHLIGHTS OF PARTNERING WITH THE ELF

- For charities, foundations, and other not-for-profits only
- Access to our state-of-the-art ELF screening facilities
- Screening of the full ELF compound library
- Triaging of primary hits
- A Qualified Hit List of max. 50 compounds
- Resynthesis and retesting of the most promising hit compounds
- Access rights and exclusivity to exploit the results
- Full control of programme progression
- Opportunity to start partnering discussions with collaborators of the ELF
- Become part of the ELF network of experts in the area of drug discovery
- Translate your ideas into medicine

GET IN TOUCH

programme@europeanleadfactory.eu
www.europeanleadfactory.eu

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).
THE EUROPEAN LEAD FACTORY: 
BRINGING TOGETHER 
esthetic drug discovery 
 stakeholders 

to translate ideas into medicine